Dinutuximab beta

Dinutuximab beta is used to treat a type of cancer called neuroblastoma, where a cancerous growth (tumour) develops in the nerve cells. Dinutuximab beta is a ‘biologic’ medicine, that is, it is a manmade version of a naturally occurring antibody. It works by stopping the neuroblastoma cells from growing. This page from Great Ormond Street Hospital (GOSH) explains what dinutuximab beta is, how it is given and some of the possible side 
Dinutuximab beta is given as an infusion into a vein (intravenously or IV), through a central venous catheter or implantable port. 
 
Dinutuximab beta is given in five courses, each of which lasts 35 days. It is given continuously (24 hours a day) for 10 days of each course followed by a 25 day break without the infusion. It may be given at home using a portable infusion pump.
 
Antihistamine medicine to stop an allergic reaction is given before the infusion is started and then regularly during the infusion. 
 
Pain is common when treatment is started so all patients tend to be given regular pain relief in the form of paracetamol, gabapentin and morphine. 

Effects on the unborn child

Dinutuximab beta must not be given to girls who may be pregnant or are likely to become pregnant in the near future. If your daughter is ten years old or older, we will ask her about her periods and any possibility that she could be pregnant. We will also carry out a pregnancy test on a fresh urine sample. If your daughter is sexually active, she must use a reliable form of contraception.

What are the side effects?

Allergic reaction

Some people receiving dinutuximab beta have an allergic reaction to the medicine. This reaction may be mild to severe. 
 
Signs of a mild allergic reaction include skin rashes and itching, high temperature, shivering, redness of the face, a feeling of dizziness or headache. If you see any of these signs, please report them to a doctor or nurse.
 
Signs of a severe allergic reaction include any of the above, as well as shortness of breath. If you are in hospital and your child shows signs of a severe allergic reaction, call a doctor or nurse immediately.

Altered blood counts

There will be a temporary reduction in how well your child’s bone marrow works. This means they may become anaemic (reduced blood cells), bruise or bleed more easily than usual, and have a higher risk of infection.
 
Your child’s blood counts will be checked regularly to see how the bone marrow is working. Please tell your doctor if your child seems unusually tired, has bruising, bleeding, or any signs of infection, especially a high temperature.

Fluid retention

If you notice any swelling or puffiness around your child’s limbs, especially the ankles, please tell your doctor or nurse.

Cough

This can be a sign of fluid building up around the lungs. If your child develops a cough, breathing difficulties and/or chest pain, tell your doctor immediately.

Headache

Tell the doctor if your chid has a headache as the dose of pain relief may need to be increased. 

Upset stomach, nausea and vomiting

Anti-sickness medicines can be given to reduce or prevent these symptoms. Please tell your doctor or nurse if your child’s sickness is very bad or lasts for more than a few days. 
 
If your child has been prescribed anti-sickness medicine, they should have a dose 30 minutes before each dose of dinutuximab beta.

Skin rashes and blistering

This is rare but could be serious. If your child develops any redness to their skin or blisters and a raised temperature, tell your doctor immediately.

Interactions with other medicines

Some medicines can react with dinutuximab beta, altering how well it works. Always check with your doctor or pharmacist before giving your child any other medicine, including medicines on prescription from your family doctor (GP), medicines bought from a pharmacy (chemist) or any herbal or complementary medicines.

Important

Alert card

We recommend that your child carries a biological therapy alert card at all times. This could be important if your child needs emergency treatment for any reason.

Chicken pox

If your child is on dinutuximab beta and has not had chickenpox but comes into contact with someone who has chicken pox or shingles (either face to face or longer than 15 minutes in the same room), you should report to your doctor immediately as your child may be at risk of developing a more severe form of the infection an may need special treatment. If your child gets chicken pox or shingles you should also report to your doctor immediately for antibiotics to be given. If you are unsure whether your child has had chicken pox prior to starting dinutuximab beta, their immunity should be checked with a simple blood test at that time and the result entered on the parent-held monitoring card.

Immunisations

Your doctor will advise you if your child should avoid immunisation during treatment. Your child should NOT have any live vaccinations such as MMR, oral polio, chicken pox or BCG while taking dinutuximab beta. Inactivated or killed vaccines such as influenza/flu, meningitis C, pneumococcal, hepatitis, Hib, tetanus, diphtheria, whooping cough/pertussis and the killed version of the polio immunisation are permitted if the patient is stable under treatment. If you have other children who need vaccines while your child is taking dinutuximab beta, they should have these as normal, but they should also receive the ‘killed’ or inactivated polio vaccine. If you have any questions about vaccines and immunisations, please ask your doctor.
Compiled by: 
The Pharmacy team in collaboration with the Child and Family Information Group
Last review date: 
October 2019
Ref: 
2019F2162

Disclaimer

Please read this information sheet from GOSH alongside the patient information leaflet (PIL) provided by the manufacturer. If you do not have a copy of the manufacturer’s patient information leaflet please talk to your pharmacist. A few products do not have a marketing authorisation (licence) as a medicine and therefore there is no PIL.
 
For children in particular, there may be conflicts of information between the manufacturer’s patient information leaflet (PIL) and guidance provided by GOSH and other healthcare providers. For example, some manufacturers may recommend, in the patient information leaflet, that a medicine is not given to children aged under 12 years. In most cases, this is because the manufacturer will recruit adults to clinical trials in the first instance and therefore the initial marketing authorisation (licence) only covers adults and older children. 
 
For new medicines, the manufacturer then has to recruit children and newborns into trials (unless the medicine is not going to be used in children and newborns) and subsequently amend the PIL with the approved information. Older medicines may have been used effectively for many years in children without problems but the manufacturer has not been required to collect data and amend the licence. This does not mean that it is unsafe for children and young people to be prescribed such a medicine ‘off-licence/off-label’. However, if you are concerned about any conflicts of information, please discuss with your doctor, nurse or pharmacist.